This application requests support for the continuation of the Training Program """"""""Drugs of Abuse and Related Neuropeptides"""""""" at Temple University which is currently in its 20th year. The purpose of the Drug Abuse Training Program is to provide a comprehensive training experience for pre- and postdoctoral fellows in the area of drug abuse and addiction. The program is multidisciplinary in nature with 20 participating faculty residing in the Departments of Pharmacology, Microbiology and Immunology, Neuroscience, Molecular Biology, Anatomy and Cell Biology, Pathology, Physiology, Psychology, and Pharmaceutical Sciences. Historically the strengths of our faculty have been in the areas of opioid pharmacology and neuroimmunopharmacology, and these strengths continue with our researchers making substantial contributions to these fields. More recently, our expertise has expanded to include strong programs in the pharmacology of psychostimulants, cannabinoids, nicotine and HIV infectivity. The laboratory approaches are state-of-the-art and range from molecular and cellular biology to behavioral analyses. Our current program supports eight predoctoral and four postdoctoral trainees and we are requesting continuation at this level. Our predoctoral trainees are exposed to a rigorous program of didactic and laboratory experiences. Postdoctoral trainees concentrate on research during their training but participate in seminars and courses related to the field of drug abuse and additiction. The Drug Abuse Training Program also provides a variety of career development activities for all trainees, such as manuscript writing, oral communication skills, grant preparation, teaching experience, attendance at national scientific meetings, laboratory management skills, and training in the responsible conduct of science. The goal of our program is to facilitate our trainees to become productive and independent researchers highly knowledgeable in research areas that will help solve problems related to drug abuse and addiction. This program provides a strongly interactive, dynamic, and supportive environment for trainees to develop into outstanding researchers. It serves as the focus for drug abuse training and research within the University and the surrounding area.

Public Health Relevance

The goal of this Drug Abuse Training Program is to provide outstanding training experiences for doctoral Students and post-doctoral fellows in the area of drug abuse and addiction research. There is a need at the national level for well-trained competent basic science researchers in areas related to drug abuse, in order to discover new treatment and prevention strategies to combat addictive diseases and their consequences.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Institutional National Research Service Award (T32)
Project #
5T32DA007237-25
Application #
8691759
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Babecki, Beth
Project Start
1988-09-01
Project End
2015-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
25
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Temple University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Kim, Jae; Connelly, Krista L; Unterwald, Ellen M et al. (2017) Chemokines and cocaine: CXCR4 receptor antagonist AMD3100 attenuates cocaine place preference and locomotor stimulation in rats. Brain Behav Immun 62:30-34
Merkel, Steven F; Andrews, Allison M; Lutton, Evan M et al. (2017) Trafficking of adeno-associated virus vectors across a model of the blood-brain barrier; a comparative study of transcytosis and transduction using primary human brain endothelial cells. J Neurochem 140:216-230
Merkel, Steven F; Cannella, Lee Anne; Razmpour, Roshanak et al. (2017) Factors affecting increased risk for substance use disorders following traumatic brain injury: What we can learn from animal models. Neurosci Biobehav Rev 77:209-218
Philogene-Khalid, Helene L; Hicks, Callum; Reitz, Allen B et al. (2017) Synthetic cathinones and stereochemistry: S enantiomer of mephedrone reduces anxiety- and depressant-like effects in cocaine- or MDPV-abstinent rats. Drug Alcohol Depend 178:119-125
Sagar, Divya; Singh, Narendra P; Ginwala, Rashida et al. (2017) Antibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity. Sci Rep 7:2707
Andrews, Allison M; Lutton, Evan M; Cannella, Lee A et al. (2017) Characterization of human fetal brain endothelial cells reveals barrier properties suitable for in vitro modeling of the BBB with syngenic co-cultures. J Cereb Blood Flow Metab :271678X17708690
Philogene-Khalid, Helene L; Simmons, Steven J; Nayak, Sunil et al. (2017) Stereoselective Differences between the Reinforcing and Motivational Effects of Cathinone-Derived 4-Methylmethcathinone (Mephedrone) In Self-Administering Rats. ACS Chem Neurosci 8:2648-2654
Reyes, Beverly A S; Kravets, J L; Connelly, K L et al. (2017) Localization of the delta opioid receptor and corticotropin-releasing factor in the amygdalar complex: role in anxiety. Brain Struct Funct 222:1007-1026
Hicks, Callum; Gregg, Ryan A; Nayak, Sunil U et al. (2017) Glutamate carboxypeptidase II (GCPII) inhibitor 2-PMPA reduces rewarding effects of the synthetic cathinone MDPV in rats: a role for N-acetylaspartylglutamate (NAAG). Psychopharmacology (Berl) 234:1671-1681
Velasquez, Stephani; Rappaport, Jay (2016) Inflammasome Activation in Major Depressive Disorder: A Pivotal Linkage Between Psychological Stress, Purinergic Signaling, and the Kynurenine Pathway. Biol Psychiatry 80:4-5

Showing the most recent 10 out of 189 publications